JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

Search

Organon & Co

Open

BrancheGesundheitswesen

6.5 0.62

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

6.41

Max

6.83

Schlüsselkennzahlen

By Trading Economics

Einkommen

-174M

-87M

Verkäufe

81M

1.6B

KGV

Branchendurchschnitt

3.435

37.461

EPS

1

Dividendenrendite

9.27

Gewinnspanne

-5.443

Angestellte

10,000

EBITDA

124M

449M

Empfehlungen

By TipRanks

Empfehlungen

Sell

12-Monats-Prognose

+36.97% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

9.27%

2.33%

Nächstes Ergebnis

30. Okt. 2025

Nächste Dividendenausschüttung

11. Dez. 2025

Nächstes Ex-Dividendendatum

12. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-101M

2.4B

Vorheriger Eröffnungskurs

5.88

Vorheriger Schlusskurs

6.5

Nachrichtenstimmung

By Acuity

42%

58%

131 / 373 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Organon & Co Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

28. Okt. 2025, 23:50 UTC

Heiße Aktien

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28. Okt. 2025, 23:25 UTC

Ergebnisse

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28. Okt. 2025, 23:18 UTC

Ergebnisse

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28. Okt. 2025, 22:20 UTC

Ergebnisse

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28. Okt. 2025, 22:13 UTC

Ergebnisse

Wal-Mart de Mexico Net Profit Falls in 3Q

28. Okt. 2025, 21:38 UTC

Ergebnisse

Correction to Visa Sales Jump Article

28. Okt. 2025, 21:17 UTC

Ergebnisse

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28. Okt. 2025, 21:07 UTC

Ergebnisse

Visa Sales Jump as Consumers Keep Spending -- Update

28. Okt. 2025, 21:02 UTC

Ergebnisse

Mondelez Tempers Outlook as Costs Rise

28. Okt. 2025, 23:51 UTC

Market Talk

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28. Okt. 2025, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28. Okt. 2025, 23:02 UTC

Ergebnisse

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28. Okt. 2025, 23:01 UTC

Ergebnisse

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28. Okt. 2025, 22:46 UTC

Ergebnisse

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28. Okt. 2025, 22:45 UTC

Ergebnisse

SK Hynix 3Q Net KRW12.6T >000660.SE

28. Okt. 2025, 22:44 UTC

Ergebnisse

SK Hynix 3Q Rev KRW24.44T >000660.SE

28. Okt. 2025, 22:43 UTC

Ergebnisse

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28. Okt. 2025, 22:42 UTC

Ergebnisse

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28. Okt. 2025, 22:40 UTC

Ergebnisse

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28. Okt. 2025, 22:40 UTC

Ergebnisse

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28. Okt. 2025, 22:22 UTC

Ergebnisse

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28. Okt. 2025, 22:22 UTC

Ergebnisse

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28. Okt. 2025, 22:22 UTC

Ergebnisse

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28. Okt. 2025, 22:20 UTC

Ergebnisse

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28. Okt. 2025, 22:02 UTC

Ergebnisse

Review & Preview: Earnings Extravaganza -- Barrons.com

28. Okt. 2025, 21:42 UTC

Market Talk
Ergebnisse

Global Equities Roundup: Market Talk

28. Okt. 2025, 21:42 UTC

Market Talk
Ergebnisse

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28. Okt. 2025, 21:20 UTC

Ergebnisse

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28. Okt. 2025, 21:19 UTC

Ergebnisse

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28. Okt. 2025, 21:18 UTC

Ergebnisse

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Peer-Vergleich

Kursveränderung

Organon & Co Prognose

Kursziel

By TipRanks

36.97% Vorteil

12-Monats-Prognose

Durchschnitt 9.67 USD  36.97%

Hoch 14 USD

Tief 5 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Organon & Co – Dist angeboten haben.

Rating-Konsens

By TipRanks

Sell

3 ratings

0

Buy

1

Halten

2

Sell

Technischer Score

By Trading Central

8.53 / 9.18Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

No Evidence

Stimmung

By Acuity

131 / 373 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Organon & Co

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.
help-icon Live chat